Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
A phase 3 trial of Ivonescimab, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Summit Therapeutics, now recruiting.
Overview
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 is a phase 3 interventional study registered as NCT06767514 by Summit Therapeutics, with 780 participants planned, started 2025-02-27 and due to reach its primary completion in 2028-04. Interventions recorded: Ivonescimab Injection, Pembrolizumab Injection. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialPhase III Study of AK112 for NSCLC Patients
Shares Summit Therapeutics, Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma
Shares Summit Therapeutics, Ivonescimab, Pembrolizumab.
- TrialHARMONi-3
Shares Ivonescimab, Pembrolizumab, Non-small-cell lung cancer.
- TrialA Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialIvonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialAK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemor
Shares Ivonescimab, Small-cell lung cancer.
- TrialA Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
Shares Ivonescimab, Small-cell lung cancer, Non-small-cell lung cancer.